Nemaura to Host Investor Webinar on October 23rd 2018 to Provide Update on Recent Developments
October 22 2018 - 4:00AM
LOUGHBOROUGH, England - Nemaura Medical Inc.
(NASDAQ: NMRD), a medical technology company developing
sugarBEAT® as a non-invasive affordable and flexible Continuous
Glucose Monitor (CGM) for use by persons with diabetes and
pre-diabetics, will host an investor webinar and live Q&A
session on Tuesday, October 23, at 11:00 a.m. EST.
The webinar will feature a presentation by Dr. Faz Chowdhury,
CEO of Nemaura, who will discuss recent developments, key benefits
of sugarBEAT® over existing competition, target markets, and plans
for the commercial launch of sugarBEAT®, as well as key upcoming
milestones.
CGM adoption is growing rapidly amongst diabetics, with the
global total addressable market estimated at $82Bn annually. The
U.S. is the largest single market, where CGM is being used by an
estimated 2.6% (630,000 users) of all diagnosed diabetics in
2018, representing annualised growth of 117%.1
To view the webinar, please visit:
https://www.redchip.com/events/32/nemaura-medical-webinar
1 PiperJaffray Company Note DXCM Sep 5, 2018
About Nemaura Medical,
Inc.
Nemaura Medical (NMRD) is a medical technology company
developing sugarBEAT® as a non-invasive, affordable and
flexible Continuous Glucose Monitor (CGM) designed to help people
with diabetes and pre-diabetics to better manage their glucose
levels. SugarBEAT® consists of a daily disposable adhesive
skin-patch connected to a rechargeable transmitter, with an app
displaying glucose readings at five-minute intervals for periods of
up to 24 hours.
For more information visit: www.NemauraMedical.com
www.SugarBEAT.com
Cautionary Statement Regarding Forward Looking
Statements
The statements in this press release that are not historical
facts, and may constitute forward-looking statements that are based
on current expectations and are subject to risks and uncertainties
that could cause actual future results to differ materially from
those expressed or implied by such statements. Those risks and
uncertainties include, but are not limited to, risks related to
regulatory approvals and the success of Nemaura Medical’s ongoing
studies, including the safety and efficacy of Nemaura Medical’s
sugarBEAT® system, the failure of future development and
preliminary marketing efforts, Nemaura Medical’s ability to secure
additional commercial partnering arrangements, risks and
uncertainties relating to Nemaura Medical and its partners’ ability
to develop, market and sell sugarBEAT®, the availability of
substantial additional equity or debt capital to support its
research, development and product commercialization activities, and
the success of its research, development, regulatory approval,
marketing and distribution plans and strategies, including those
plans and strategies related to sugarBEAT®. These and other risks
and uncertainties are identified and described in more detail in
Nemaura Medical’s filings with the Securities and Exchange
Commission, including, without limitation, its Annual Report on
Form 10-K for the current year, its Quarterly Reports on Form 10-Q,
and its Current Reports on Form 8-K. Nemaura Medical undertakes no
obligation to publicly update or revise any forward-looking
statements.
Contacts
Nemaura Medical Inc. Bashir Timol Chief Business Officer
bashir.timol@nemauramedical.com
RedChip CompaniesVictor
Roberts407-644-4256victor@redchip.com
Nemaura Medical (NASDAQ:NMRD)
Historical Stock Chart
From Jul 2024 to Aug 2024
Nemaura Medical (NASDAQ:NMRD)
Historical Stock Chart
From Aug 2023 to Aug 2024